RBC Capital raised the firm’s price target on Arrowhead (ARWR) to $80 from $52 and keeps an Outperform rating on the shares after meeting with its management team. The recent approval of Redemplo marks a key milestone for the organization and the company remains upbeat about the early commercial traction, the analyst tells investors in a research note. The stock has had a meaningful run recently, but the non-deal-roadshow strengthens the firm’s conviction that transition to a fully integrated Biotech company may accelerate from here, especially given an organization that appears much more focused on late-stage cardiometabolic.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARWR:
- Analyst Recommends Buy Rating for Arrowhead Pharmaceuticals Due to Promising Obesity Treatment Potential
- Arrowhead price target raised to $81 from $62 at BofA
- Cautious Optimism for Arrowhead Pharmaceuticals Amid Competitor’s Positive Obesity Treatment Data
- Morgan Stanley sees positive readthrough to Arrowhead pipeline from Wave data
- Arrowhead doses first subjects in ARO-MAPT trial